Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Nomination committee appointed ahead of 2020 annual general meeting of shareholders in XMReality (publ)

As resolved by the annual general meeting of shareholders in XMReality, the nomination committee will comprise representatives of the chairman of the board and the three largest shareholders as of 30 September 2019.Ahead of the 2020 AGM, the members of the nomination committee are: · Kent Söderström, Investment Spiltan · Helen Fasth-Gillstedt, Handelsbanken Fonder · Angelica Hanson, AMF Fonder · Claes Nylander, chairman of the board, XMReality The remit of the nomination committee includes submitting proposals on the following matters: · Number of directors to be

Crown Energy AB: Interim report January-September 2019

Q3 – JULY-SEPTEMBER 2019 · Revenue amounted to SEK 13,327 thousand (18,260). · Operating profit amounted to SEK 2,528 thousand (5,468). · Net financial items amounted to SEK 27,361 thousand (21,546). · Unrealised changes in property values amounted to SEK 796 thousand (-2,957). · Profit before tax amounted to SEK 30,686 thousand (24,057), and profit after tax amounted to SEK 28,569 thousand (-3,759), corresponding to SEK 0.06 (-0.01) per share. INTERIM PERIOD– JANUARY-SEPTEMBER 2019 · Revenue amounted to SEK 38,865 thousand (57,920).  · Operating profit amounted

SKF issues its first green bond

Gothenburg, 8 November 2019: SKF has, as one of the first industrial companies, issued a green bond. The bond will raise EUR 300 million to fund eligible green projects in accordance with SKF’s recently launched Green Finance Framework. SKF’s green bond has received much attention from investors and it was oversubscribed four times. The proceeds from the bond will finance green investments that reduce CO2 emissions and impact from SKF’s own operations and supply chain operations, as well as supporting customers to reduce their emissions. This will be done through capital investment in

Volati changes its ownership of me&i

Volati AB (publ) has changed its ownership of me&i, a business unit in the Consumer business area. Volati previously owned 65 percent of the shares in the business unit, but has now converted the ownership into preference shares, with me&i’s former minority shareholders becoming the new majority shareholders of the company. The change means that Volati is entitled to receive up to SEK 78 million in future payments from me&i. After the change in ownership, the carrying amount of Volati’s preference shares and receivables is SEK 12 million and Volati no longer consolidates me&i. In

Swedavia’s traffic statistics for October 2019

In October, 3,531,000 passengers flew via Swedavia’s ten airports, which is a decrease of almost 5 per cent compared to the same month last year. This month, a continued weaker trend for domestic travel was noted, while international traffic decreased to a lesser extent and scheduled European traffic was basically unchanged compared to October last year. The total number of international passengers at Swedavia’s airports was 2,378,000 in October, which is a decrease of almost 2 per cent compared to the same month last year. The total number of domestic passengers was 1,153,000 passengers,

Significant Contract Award by Woodside

Solstad Offshore ASA (“Solstad”) has entered into a contract with Woodside for the provision of six vessels, of which two are Anchor Handlers and four are Platform Supply Vessels, to provide marine services for several offshore drilling campaigns in Australian waters commencing in December 2019. Normand Saracen, Far Senator, Normand Leader, Normand Skimmer, Normand Swan and Far Seeker will be contracted to Woodside for a combined firm period of 1100 vessel-days, with Woodside having access to a further combined total of 3000 optional vessel-days. The Normand Leader, a dual fuel

INTERIM REPORT Period from January 2019 to September 2019 Peptonic Medical AB (publ) org nr 556776-3064 (www.aktietorget.se ticker: PMED)

2019 THIRD QUARTER (Jul-Sep) · Net sales of products KSEK 1,557 (120) · Gross profit KSEK 692 (95), Gross margin 45% (79%) · Operating loss KSEK -4,127 (-3,420)  · Loss per share SEK -0.03 (-0.04) FIRST NINE MONTHS 2019 (Jan-Sep) · Net sales of products KSEK 4,073 (120) · Gross profit KSEK 2,321 (95), Gross margin 57% (79%) · Operating loss KSEK -12,414 (-9,739)  · Loss per share SEK -0.10 (-0.11)From the CEO The third quarter can be described as a period of activities and events to continue building the foundation of the future Peptonic. Many long-term

Climeon's nomination committee for the Annual General Meeting 2020

The nomination committee of Climeon AB (publ) for the Annual General Meeting 2020 (AGM) is hereby announced, which consists of the following representatives appointed by the largest shareholders as per 30 September 2019 as well as the Chairman of the Board: · Helen Öström, appointed by the shareholder Thomas Öström (53,6% of the votes and 19,6% of the shares) · Anne Holm Rannaleet, appointed by Joachim Karthäuser (26,4% of the votes and 9,5% of the shares) · Niklas Johansson, appointed by Handelsbanken Fonder (0,7% of the votes and 2,3% of the shares)  · Annelie Enquist,

HDV fleet owners in Finland and Sweden see an environment-focused mindset as a permanent phenomenon

A recent survey analyzed how environmental issues are viewed by Finnish and Swedish heavy-duty vehicle (HDV) fleet owners. According to the results, customers’ environmental expectations have increased in both Finland and Sweden, and 82% of fleet owners in both countries agree that an environment-focused mindset is a permanent phenomenon and not a passing trend. Liquefied natural gas (LNG) and liquefied biogas (LBG) are low-emission fuel alternatives for road transport that are also cost effective.The Nordic energy company Gasum commissioned Value Clinic to conduct a survey on how Finnish

Finnair Plc - Managers' transactions – Suominen

Finnair Plc, Managers’ Transactions, 8 November 2019 at 09:05 am EET ____________________________________________ Person subject to the notification requirement Name: Suominen, Arja Position: Other senior manager Issuer: Finnair Plc LEI: 213800SB6EOB8SSK9W63 Notification type: INITIAL NOTIFICATION Reference number: 213800SB6EOB8SSK9W63_20191107122016_116 ____________________________________________ Transaction date: 2019-11-05 Venue: XHEL Instrument type: SHARE ISIN: FI0009003230 Nature of the transaction: ACQUISITION Further details: Quarterly

Finnair Plc - Managers' transactions – Schildt

Finnair Plc, Managers’ Transactions, 8 November 2019 at 09:04 am EET ____________________________________________ Person subject to the notification requirement Name: Schildt, Jaakko Position: Other senior manager Issuer: Finnair Plc LEI: 213800SB6EOB8SSK9W63 Notification type: INITIAL NOTIFICATION Reference number: 213800SB6EOB8SSK9W63_20191107122016_119 ____________________________________________ Transaction date: 2019-11-05 Venue: XHEL Instrument type: SHARE ISIN: FI0009003230 Nature of the transaction: ACQUISITION Further details: Quarterly

Finnair Plc - Managers' transactions – Manner

Finnair Plc, Managers’ Transactions, 8 November 2019 at 09:03 am EET ____________________________________________ Person subject to the notification requirement Name: Manner, Topi Position: Chief Executive Officer Issuer: Finnair Plc LEI: 213800SB6EOB8SSK9W63 Notification type: INITIAL NOTIFICATION Reference number: 213800SB6EOB8SSK9W63_20191107122016_115 ____________________________________________ Transaction date: 2019-11-05 Venue: XHEL Instrument type: SHARE ISIN: FI0009003230 Nature of the transaction: ACQUISITION Further details: Quarterly

Metsä Fibre’s Botnia pulp is now called Metsä pulp

Metsä Fibre press releaseMetsä Fibre, part of Metsä Group, is renewing its pulp product brand. The Botnia brand will be replaced by the Metsä brand in all pulp products, services and biochemicals. We want to strengthen our Metsä brand, and refresh our branding and marketing to focus more on our customers. The pulp branding is new, but the products and product range are exactly the same, with the same Northern wood raw material and guaranteed Metsä Fibre quality.  “We are simplifying the naming of our pulp product and service portfolio by moving  our pulp offering under one unified

Finnair Plc - Managers' transactions – Karhu

Finnair Plc, Managers’ Transactions, 8 November 2019 at 09:02 am EET ____________________________________________ Person subject to the notification requirement Name: Karhu, Piia Position: Other senior manager Issuer: Finnair Plc LEI: 213800SB6EOB8SSK9W63 Notification type: INITIAL NOTIFICATION Reference number: 213800SB6EOB8SSK9W63_20191107122016_118 ____________________________________________ Transaction date: 2019-11-05 Venue: XHEL Instrument type: SHARE ISIN: FI0009003230 Nature of the transaction: ACQUISITION Further details: Quarterly

Humana reports third quarter results 2019

Good growth, improved customer satisfaction and better resultsThird quarter, July-September 2019 · Operating revenue was SEK 1,928 million (1,677), an increase of 15%. The organic growth was 3.2%. · Operating profit was SEK 176m (151), an increase of 17%. Excluding the effects of IFRS 16, the standard for recognising leases that applies from 1 January 2019, operating profit amounted to SEK 164m (151), an increase of 9%. · Net profit after tax for the period amounted to SEK 128m (102). Excluding the effects of IFRS 16, profit after tax amounted to SEK 134m (102). · Earnings per

Finnair Plc - Managers' transactions – Ilebrand

Finnair Plc, Managers’ Transactions, 8 November 2019 at 09:01 am EET ____________________________________________ Person subject to the notification requirement Name: Ilebrand, Nicklas Position: Other senior manager Issuer: Finnair Plc LEI: 213800SB6EOB8SSK9W63 Notification type: INITIAL NOTIFICATION Reference number: 213800SB6EOB8SSK9W63_20191107122016_117 ____________________________________________ Transaction date: 2019-11-05 Venue: XHEL Instrument type: SHARE ISIN: FI0009003230 Nature of the transaction: ACQUISITION Further details:

INTERIM REPORT 1 JANUARY – 30 SEPTEMBER 2019

Third quarter (1 July – 30 September 2019) · Net sales for the quarter amounted to MSEK 58 (150). · Operating profit/loss before depreciation and amortisation excluding associates (adjusted EBITDA) totalled MSEK 22 (90), and including associates (EBITDA) totalled MSEK 21 (90). · Operating profit/loss excluding associates (adjusted EBIT) amounted to MSEK 3 (72), and including associates (EBIT) totalled MSEK 2 (72). · Profit/loss before tax excluding associates (adjusted EBT) amounted to MSEK -15 (53), and including associates (EBT) totalled MSEK -16 (53). · Profit/loss after

Kamux Corporation’s Interim Report for January 1 - September 30, 2019

Kamux Corporation         Interim Report                                November 8, 2019 at 09:00 Kamux Corporation’s Interim Report for January 1 - September 30, 2019 Kamux continued its strong and profitable growth: Revenue increased by 30.6% and adjusted operating profit by 29.0% The figures in parenthesis refer to the comparison period, i.e. the same period in the previous year, unless stated otherwise. July-September in brief - Revenue increased by 30.6%, totaling EUR 182.8 million (140.0) - Gross profit increased by 27.1% to EUR 22.8 million (18.0), or 12.5% (12.8)

Interim report January-September 2019

Gothenburg, November 8, 2019 - Vicore Pharma Holding AB (publ) publish the interim report for the third quarter 2019.Important events during the third quarter · In September, Vicore Pharma announced the outcome of the dose escalation phase I study with VP01 (C21). The study established that 200 mg daily has a good safety profile and that it was the maximum tolerated dose. This dose will be used in the planned phase II studies in idiopathic pulmonary fibrosis (IPF) and systemic sclerosis (SSc). · In September, Vicore was approved for uplisting to Nasdaq Stockholm. First day of

Loi Krathong Festival 2019

The full moon night of the 12[th] lunar month this year falls on 11 November and it marks one of the most magnificent and unique Thai tradition of the year, “Loi Krathong” (Krathong is a floating basket made from variety of natural materials such as banana leaf and flowers)   “Loi Krathong is among Thailand’s most impressive cultural events. It takes place during one of the best times in Thailand when there is a full moon in the sky, the weather is nice and cool, and the foliage is green from the annual rainy season. “On the day, many Thais float their krathong down a

Eastnine: Interim Report January ‒ September 2019

1 January – 30 September 2019 · Rental income increased by 39 per cent to EUR 9,187k (6,614) due to an expanded property portfolio. On an identical portfolio, rental income decreased by 12 per cent due to lower average occupancy rate during the period. · Net operating income increased by 47 per cent to EUR 8,196k (5,569). · Profit from property management increased by 81 per cent to EUR 3,790k (2,095). · Unrealised value changes amounted to EUR 11,587k (1,201) of which EUR 6,294k (4,620) is attributable to Real Estate Direct, EUR -1,707k (-164) to interest rate derivatives,

Preparations for Phase III study with Mangoral[®] on track

Ascelia Pharma AB (publ) (ticker: ACE) today published its first quarter interim report for the period July 2019 – September 2019, which is now available on the company’s website: https://www.ascelia.com/tag/reports-presentations/SIGNIFICANT EVENTS IN THE PERIOD · Detailed preparations for the start of the Phase III study for Mangoral (study name SPARKLE) · The Phase III study will be conducted in Europe, the US and South Korea SIGNIFICANT EVENTS AFTER THE PERIOD · Dorthe Thrige, COO, will be leaving the company FINANCIAL SUMMARY Q1 2019/2020 (JUL-SEP 2019) ·

Roxadustat significantly increased haemoglobin levels for chronic kidney disease patients with anaemia in Phase III OLYMPUS and ROCKIES trials

8 November 2019 07:00 GMT  Roxadustat significantly increased haemoglobin levels for chronic kidney diseasepatients with anaemia in Phase III OLYMPUS and ROCKIES trials  OLYMPUS demonstrated a mean increase of 1.75g/dL averagedover weeks 28 to 52, compared to 0.40g/dL with placebo ROCKIES demonstrated a mean increase of 0.77g/dL averagedover weeks 28 to 52, compared to 0.68g/dL with epoetin alfa   AstraZeneca today presented detailed results from the Phase III OLYMPUS and ROCKIES trials showing that roxadustat significantly increased haemoglobin (Hb) levels in non-

Third Quarter Interim report January - September 2019

Strong sales growth – positive development with increased profitability 1 July–30 September 2019 · Net sales amounted to SEK 2,879 M (1,850). Net sales rose 56 per cent, of which 2 percentage points in organic growth. · Adjusted EBIT amounted to SEK 231 M (148) and the adjusted EBIT margin was 8 per cent (8). · EBIT totalled SEK 191 M (118) and the EBIT margin was 7 per cent (6). EBIT was not impacted by items affecting comparability in the quarter (neg: SEK 4 M). · Positive impact of IFRS 16 of SEK 5 M on EBIT and adjusted EBIT. · Earnings per share, before and after

There are no items matching the current filter
There are no more items matching the current filter
Back to top